Solriamfetol hydrochloride


Entry
D11328                      Drug                                   
Name
Solriamfetol hydrochloride (USAN);
Sunosi (TN)
Product
SUNOSI (Axsome Therapeutics), SUNOSI (Jazz Pharmaceuticals)
Formula
C10H14N2O2. HCl
Exact mass
230.0822
Mol weight
230.6913
Structure
Simcomp
Class
Neuropsychiatric agent
 DG03059  Noradrenalin and dopamine reuptake inhibitor (NDRI)
Remark
ATC code: N06BA14
Chemical structure group: DG02989
Product (DG02989): D11328<US>
Efficacy
Wake-promoting agent, Noradrenalin and dopamine reuptake inhibitor
  Disease
Narcolepsy [DS:H01293]
Comment
Wake-promoting agent for the treatment of excessive sleepiness associated with narcolepsy or obstructive sleep apnea
Target
SLC6A2 (NAT1) [HSA:6530] [KO:K05035]
SLC6A3 (DAT1) [HSA:6531] [KO:K05036]
  Pathway
hsa04721  Synaptic vesicle cycle
hsa04728  Dopaminergic synapse
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 N NERVOUS SYSTEM
  N06 PSYCHOANALEPTICS
   N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
    N06BA Centrally acting sympathomimetics
     N06BA14 Solriamfetol
      D11328  Solriamfetol hydrochloride (USAN) <US>
USP drug classification [BR:br08302]
 Sleep Disorder Agents
  Wakefulness Promoting Agents
   Solriamfetol
    D11328  Solriamfetol hydrochloride (USAN)
Drug groups [BR:br08330]
 Neuropsychiatric agent
  DG03059  Noradrenalin and dopamine reuptake inhibitor (NDRI)
   DG02989  Sorliamfetol
    D11328  Solriamfetol hydrochloride
Target-based classification of drugs [BR:br08310]
 Transporters
  Solute carrier family
   SLC6
    SLC6A2 (NAT1)
     D11328  Solriamfetol hydrochloride (USAN) <US>
    SLC6A3 (DAT1)
     D11328  Solriamfetol hydrochloride (USAN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11328
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11328
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11328
Drug groups [BR:br08330]
 Neuropsychiatric agent
  DG03059  Noradrenalin and dopamine reuptake inhibitor (NDRI)
   DG02989  Sorliamfetol
Other DBs
CAS: 178429-65-7
PubChem: 384585306
KCF data

ATOM        15
            1   C8x C    13.7981  -16.1795
            2   C8x C    13.7981  -17.5803
            3   C8x C    15.0589  -18.2807
            4   C8x C    16.2496  -17.5803
            5   C8y C    16.2496  -16.1795
            6   C8x C    15.0589  -15.4791
            7   C1b C    17.5103  -15.4791
            8   C1c C    18.7010  -16.1795
            9   C1b C    19.8917  -15.4791
            10  O7a O    21.0824  -16.1795
            11  C7a C    22.2731  -15.4791
            12  N1a N    23.4638  -16.1795
            13  O6a O    22.2731  -14.0783
            14  N1a N    18.7010  -17.5803
            15  X   Cl   26.6000  -18.2000
BOND        14
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     7   8 1
            9     8   9 1
            10    9  10 1
            11   10  11 1
            12   11  12 1
            13   11  13 2
            14    8  14 1 #Down